ArticleDEN open2026
Dilation Device Use and Concomitant Antegrade Stenting are Associated With Procedure-related Early Adverse Events After Endoscopic Ultrasound-guided Hepaticogastrostomy: A Retrospective Multicenter Study.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) is useful in cases of endoscopic retrograde cholangiopancreatography failure. However, the procedure has a high incidence of procedure-related early adverse events (PRAEs). This study retrospectively evaluated risk factors for such events post-EUS-HGS. Methods: This multicenter study included 222 patients (120 males and 102 females; median age = 73 years) who underwent initial EUS-HGS. The clinical success rate and PRAE incidence, and risk factors were analyzed. PRAEs were defined as AEs occurring within 2 weeks. Results: The median procedure time was 41 min. Metal or plastic stents were used for EUS-HGS in 107 and 115 patients, respectively. Fistula dilation and concomitant antegrade stenting (AGS) were performed in 166 and 45 patients, respectively. The clinical success rate and PRAE incidence were 85.1% and 22.1%, respectively. Identified PRAEs included acute peritonitis (9.5%), fever (6.8%), abdominal pain (2.3%), and acute pancreatitis (1.4%). Multivariate analysis identified dilation device use ( Conclusions: Fistula dilation and AGS are associated with an increased risk of PRAEs post-EUS-HGS. Careful postoperative follow-up for such events is required in patients undergoing fistula dilation for EUS-HGS with AGS and prolonged procedure time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.